Russian scientists hail results of COVID-19 vaccine trial

MOSCOW (Reuters) - Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine on Wednesday, saying it had been proved safe and that volunteers had developed an immune response.

Reuters July 16, 2020 00:18:22 IST
Russian scientists hail results of COVID-19 vaccine trial

COVID-19 vaccine trial" src="https://images.firstpost.com/wp-content/uploads/reuters/07-2020/16/2020-07-15T132115Z_1_LYNXNPEG6E10F_RTROPTP_2_HEALTH-CORONAVIRUS-RUSSIA-VACCINE.jpg" alt="Russian scientists hail results of COVID19 vaccine trial" width="300" height="225" />

MOSCOW (Reuters) - Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine on Wednesday, saying it had been proved safe and that volunteers had developed an immune response.

Speaking to a crowded room without wearing masks, three of 18 volunteers monitored over a month at the Sechenov University said they all had experienced few side-effects.

A larger-scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August.

More than 100 possible vaccines are being developed and tested around the world to try to stop the pandemic. Of 19 in human trials, only two are in the final Phase III - one by China's Sinopharm and another by AstraZeneca and the University of Oxford.

"We were primarily testing for safety," Elena Smolyarchuk, a department director at Sechenov University and one of the coordinators of the trial, said.

"On non-specific immunity we can only talk about preliminary results. These show a good, positive tendency, a strengthening of non-specific immunity," she said.

However any final conclusions about the immune response among the volunteers will be drawn by the Gamaleya Institute, which developed the vaccine, and are expected towards the end of the month.

Russia's health ministry will then decide whether to register the vaccine and begin a larger-scale trial, Smolyarchuk said.

The vaccine is administered in two doses and consists of two serotypes of the human adenovirus, each carrying an S-antigen of the new coronavirus , which enter human cells and produce an immune response, Smolyarchuk said.

It was first tested on primates and then administered to the volunteers on June 18.

The platform used for the vaccine was developed by Russian scientists over two decades and had formed the basis for several vaccines in the past, including three against Ebola, the Sechenov University's Vadim Tarasov said.

The defence ministry, which conducted a parallel trial of the same vaccine on a separate set of 20 volunteers, also said on Wednesday the group had been discharged.

"It's not scary anymore," Yuriy, a soldier and volunteer, said in a video shared by the Ministry of Defence.

($1 = 70.8755 roubles)

(Reporting by Polina Ivanova; Editing by Nick Macfie)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

Under-supplied palladium races to record, gold awaits Fed
Business

Under-supplied palladium races to record, gold awaits Fed

By Eileen Soreng (Reuters) - Palladium prices hit a record on Tuesday, spurred by persistent supply worries, while gold held a narrow range as investors awaited policy signals from the U.S. Federal Reserve's meeting this week. Palladium hit a record of $2,962.50 per ounce earlier and was up 0.8% at $2,948.69 per ounce by 1:02 p.m

General Electric reports smaller cash outflow, reaffirms 2021 outlook
Business

General Electric reports smaller cash outflow, reaffirms 2021 outlook

By Rajesh Kumar Singh and Ankit Ajmera (Reuters) -General Electric's cash outflow was smaller than estimated in the first quarter even as its lucrative jet-engine business struggled with the pandemic-led collapse of air travel, driving down company revenue. The company also reaffirmed its full-year free cash flow and earnings per share outlook

Oil rises as OPEC+ seen sticking to policy despite India COVID surge
Business

Oil rises as OPEC+ seen sticking to policy despite India COVID surge

By Devika Krishna Kumar NEW YORK (Reuters) - Oil prices edged higher on Tuesday as OPEC+ was expected to stick to existing plans to boost oil output slightly from May 1, suggesting it does not see a lasting impact on demand from India's coronavirus crisis. The group has also ditched plans to hold a full ministerial meeting on Wednesday, sources said. A technical meeting on Monday had voiced concern about surging COVID-19 cases but kept its oil demand forecast unchanged.